Evidence map›Paper›PMID 30249030›Full record

ArticleMolecules (Basel, Switzerland)2018

KMUP-1, a GPCR Modulator, Attenuates Triglyceride Accumulation Involved MAPKs/Akt/PPARγ and PKA/PKG/HSL Signaling in 3T3-L1 Preadipocytes.

Chung-Pin Liu, Pei-Chun Chau, Chain-Ting Chang, Li-Mei An, Jwu-Lai Yeh, Ing-Jun Chen, Bin-Nan Wu

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Chung-Pin LiuDepartment of Cardiology, Yuan's General Hospital, Kaohsiung 802, Taiwan. liuchungpin@yahoo.com.tw.
Pei-Chun ChauDepartment of Pharmacology, Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. b9220@hotmail.com.
Chain-Ting ChangDepartment of Pharmacology, Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. a99443@hotmail.com.
Li-Mei AnDepartment of Pharmacology, Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. anlm@kmu.edu.tw.
Jwu-Lai YehDepartment of Pharmacology, Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. jwulai@kmu.edu.tw.ORCID 0000-0001-7101-5865
Ing-Jun ChenDepartment of Pharmacology, Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. ingjun@kmu.edu.tw.
Bin-Nan WuDepartment of Pharmacology, Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. binnan@kmu.edu.tw.ORCID 0000-0001-6593-5120
Kaohsiung Medical University · TWYuan's General Hospital · TW

Funding

Ministry of Science and Technology, Taiwan MOST 106-2320-B-037-009-MY3
6 · The paper itself

Abstract

Xanthine-based KMUP-1 was shown to inhibit phosphodiesterases (PDEs) and modulate G-protein coupled receptors (GPCRs) to lower hyperlipidemia and body weight. This study further investigated whether KMUP-1 affects adipogenesis and lipolysis in 3T3-L1 preadipocytes. KMUP-1 (1⁻40 µM) concentration-dependently attenuated Oil Red O (ORO) staining and decreased triglyceride (TG) accumulation, indicating adipogenesis inhibition in 3T3-L1 cells. In contrast, the β-agonist ractopamine increased ORO staining and TG accumulation and adipogenesis. KMUP-1 (1⁻40 µM) also reduced MAPKs/Akt/PPARγ expression, PPARγ1/PPARγ2 mRNA, and p-ERK immunoreactivity at the adipogenesis stage, but enhanced hormone sensitive lipase (HSL) immunoreactivity at the lipolysis stage. Addition of protein kinase A (PKA) or protein kinase G (PKG) antagonist (KT5720 or KT5728) to adipocytes did not affect HSL immunoreactivity. However, KMUP-1 did increase HSL immunoreactivity and the effect was reduced by PKA or PKG antagonist. Simvastatin, theophylline, caffeine, and sildenafil, like KMUP-1, also enhanced HSL immunoreactivity. Phosphorylated HSL (p-HSL) was enhanced by KMUP-1, indicating increased lipolysis in mature 3T3-L1 adipocytes. Decreases of MAPKs/Akt/PPARγ during adipogenesis contributed to inhibition of adipocyte differentiation, and increases of PKA/PKG at lipolysis contributed to HSL activation and TG hydrolysis. Taken together, the data suggest that KMUP-1 can inhibit hyperadiposity in 3T3-L1 adipocytes.

Indexed as

3T3-L1 CellsAdipocytesAdipogenesisAnimalsCyclic AMP-Dependent Protein KinasesCyclic GMP-Dependent Protein KinasesGene Expression RegulationLipolysisMiceMitogen-Activated Protein KinasesPhosphorylationPiperidinesPPAR gammaProto-Oncogene Proteins c-aktSignal TransductionSterol EsteraseCyclic AMP-Dependent Protein KinasesCyclic GMP-Dependent Protein KinasesKMUP 1Mitogen-Activated Protein KinasesPiperidinesPPAR gammaProto-Oncogene Proteins c-aktSterol EsteraseTriglyceridesXanthinesadipogensislipolysisMAPKphosphorylated HSLPPARγprotein kinases

Identifiers

PMID30249030
PMCPMC6222827
OpenAlexW2891306502

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.